Upregulation of ligands and receptors provides handy targets for antibodies and ADCs
Anyone who has been casually following oncology R&D over the last five years might be forgiven for thinking the gold rush and panning for nuggets in IO might have overtaken company interest in targeted therapies, whether they be small molecules, antibodies, or ADCs.
As hematologic malignancies evolve, proteins are upregulated on the surface of the cancer cells, providing a variety of novel targets to aim at therapeutically.
For those in the know, however, the quality of research in the targeted niche remains at a very high level with some serious research going on behind the scenes in terms of novel targets, focused clinical developments (i.e. not treating a targeted agent in an untargeted fashion), and even enhanced design of next generation molecules coming to the fore…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH20 virtual conference — including our second meeting Preview — subscribers can log-in or you can click to gain access to BSB Premium Content.
A path through the CD47 wilderness?
Continuing the third part of our ongoing CD47-SIRPα mini-series, we move on from the science and the competitive landscape to look at what CEOs in this niche have to say. There are many different approaches being evaluated at present, mostly in preclinical development, which makes it an intriguing area to potentially follow over time as new data emerges.
Not all of these molecules will be successful and the target is certainly not the easiest to attempt, although not as diffcult as MYC or RAS either!
When all is said an done, what do key players in this field think when they are developing compounds and how do they see the emerging challenges?
In this latest post, we have not one, but two CEOs, who were willing who share their candid thoughts and perceptions on the CD47-SIRPα space…
To learn more from thought leaders and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Choose your clinical gateway!
When an oncology R&D landscape starts getting crowded and highly competitive, how do you go about working out clinically meaningful differences between compounds in development?
After all, there are often a myriad of small differences and nuances in the preclinical approach that may or may not be useful when it comes to the clinic.
Sometimes design matters, whether this be in the way the molecules are built or function, perhaps in tumour types that are selected for study, while at other times trial design can impact outcome. In short, much like a 3D chess game it can get complicated pretty fast.
One such area that has been receiving increased attention lately and also has a lot of complexity to consider is the CD47-SIRPα pathway.
Last week we covered some of the key basics in a primer exploring the science in Part 1 of this mini-series.
Tomorrow we will post Part 3, which focuses on candid comments from researchers and CEOs in this niche, but before we get there it’s time to look at key clinical perspectives, as well as some of the nuances from related pathways that may be important factors to consider.
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.